. Metaanalyses failed to demonstrate clinical benefits of beta lactam plus aminoglycoside combination therapy compared to beta lactam monotherapy in patients with sepsis. However, few data exist on the effects of short-course adjunctive aminoglycoside therapy in sepsis patients with organ failure or shock.
Aminoglycoside antibiotics are frequently used in critically ill patients for the treatment of sepsis, especially in those with sepsis of unknown or suspected abdominal origin [1] . Pharmacological properties of aminoglycosides include fast and concentration-dependent killing of bacteria, which persists after antibiotic clearance (post-antibiotic effect) [2] . Moreover, addition of an aminoglycoside broadens the antibacterial spectrum, which in an era of increasing antimicrobial resistance may reduce the risk of providing inadequate treatment. However, despite these potential advantages, controversy exists on their added value in the empirical treatment of sepsis because of adverse effects, including a reported 3-fold increased risk of nephrotoxicity [3] . This is particularly relevant following prolonged courses of treatment and involve use of multiple daily dosing [3] . Of note, kidney injury may be more pronounced for gentamicin compared to tobramycin because of greater accumulation of the drug in proximal renal tubules [4] .
Clinical trials and metaanalyses have failed to demonstrate beneficial effects of aminoglycoside-beta lactam combination therapy compared to beta lactam monotherapy on survival of patients with sepsis [3] . However, despite these findings, the use of short courses of gentamicin in critically ill sepsis patients is still prevalent [5, 6] and even advocated in several guidelines [7] [8] [9] . It has been argued that in the subgroup of the most severely ill, such as those with organ failure or shock, the empirical addition of gentamicin may result in faster reversal of clinical symptoms [1] and that nephrotoxicity is usually mild as long as the drug is administered for only a short period of time [10] . Yet, intensive care unit (ICU) patients are vulnerable to development of renal failure because of frequent coexisting diseases and presence of other risk factors for acute kidney injury (AKI) [11, 12] .
Our aim in this study was to determine the effects of a short add-on course of gentamicin on the rates of AKI, reversal of shock, and death in critically ill patients who were admitted to the ICU with severe sepsis or septic shock.
METHODS

Study Design
We studied consecutive patients who presented with severe sepsis or septic shock and stayed for at least 24 hours in the mixed medical-surgical ICUs of 2 tertiary care hospitals in the Netherlands. Clinical management of sepsis was in accordance with Surviving Sepsis Campaign guidelines in both centers [13] , but local antibiotic protocols differed. For patients with sepsis of unknown origin (or those with a clinical suspicion of an abdominal or urinary focus of infection), a third-generation cephalosporin (plus metronidazole) was recommended as empirical treatment in both ICUs, with the addition of gentamicin (initial dosing 5 mg/kg bodyweight, with follow-up dosing guided by therapeutic drug monitoring) for a maximum of 3 days recommended in hospital A, but not in hospital B (Supplementary Table 1 ). Streamlining of antibiotic therapy based on culture results was practiced in both ICUs.
Data were prospectively collected within the framework of the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) cohort [14] . Patients were enrolled between January 2011 and December 2013 (hospital A) and between January 2011 and December 2015 (hospital B). The criteria for diagnosing severe sepsis or septic shock were applied as described in more detail previously [15] . However, all included patients also fulfilled the new Sepsis-3 criteria [16] . All patients with a post hoc likelihood of infection that was rated possible, probable, or definite were included. Infections were classified by dedicated observers according to the Centers for Disease Control and Prevention and International Sepsis Forum Consensus Conference definitions that were translated and adapted to the Dutch situation [14] . Patients with suspected pneumonia or central nervous system infections were excluded because gentamicin was not recommended as initial antibiotic therapy for these indications in either hospital. Likewise, patients with sepsis due to endocarditis were excluded because gentamicin was indicated according to the protocols of both hospitals and also is usually given in a lower dose in this setting. Finally, patients who already required renal replacement therapy (ie, hemodialysis or peritoneal dialysis) before ICU admission were excluded.
Inappropriate gram-negative antimicrobial coverage was defined as receipt of antibiotics within the first 24 hours that did not cover gram-negative microorganisms present in microbiological cultures obtained between 2 days before and 2 days after ICU admission.
The institutional review board, UMC Utrecht approved an opt-out consent method (protocol number 10-056C). Participants and family members were notified of the study by a brochure provided at ICU admission with attached an opt-out card that could be completed by the patient or by his or her legal representative in case they declined to participate.
Study Outcomes
The primary outcome for analysis was the number of days alive and free of renal failure on day 14 after sepsis onset. This composite endpoint was chosen because increased mortality may falsely decrease both incidence and duration of renal failure in the most severe cases. Renal failure was defined as risk, injury, failure, loss, and end-stage kidney disease (RIFLE) stage ≥3 (ie, 3-fold serum creatinine increase, urine output <0.3 mL/kg/h for 24 hours or anuria for >12 hours and/or any use of renal replacement therapy). Secondary outcomes were the number of days alive and free of shock on day 14, and mortality until day 14. For this purpose, shock was defined as a sequential organ failure assessment (SOFA) circulatory component of 4 (ie, norepinephrine or epinephrine use >100 ng/kg/min).
Analyses
We used ordinal logistic regression analyses to assess the associations of gentamicin use with renal failure and cardiovascular shock. To this end, the number of renal failure-free days alive on day 14 and the number of shock-free days alive on day 14 were each collapsed into 3 ordinal levels, making sure that the observed frequency of events reached at least 20% in each level. Subsequently, we checked the proportional odds assumption using the score test. Logistic regression was used for the analysis of 14-day mortality. All primary effect estimates were based on a per protocol analysis (ie, by comparing patients with and without actual gentamicin exposure), because potential differences in patient populations and unmeasured aspects of care between both hospitals are less likely to confound the outcome association in this type of analysis. However, to assess possible bias caused by confounding by indication, an intention-totreat analysis (ie, comparing all patients between hospitals with and without protocolized gentamicin use) was performed as a sensitivity analysis. Furthermore, we performed additional sensitivity analyses in several subgroups of patients. First, we evaluated day-14 survivors only to assess the effects of gentamicin use on the incidences and durations of renal failure and shock conditional on survival status. Second, we evaluated patients with abdominal sepsis, because the potential benefit of adjunctive gentamicin treatment might be greatest in these patients due to a relatively large contribution of gram-negative pathogens.
For all multivariable models we decided a priori to adjust for the following patient characteristics known to be associated with renal failure and/or mortality: age, ethnicity, medical vs surgical reason for ICU admission, SOFA score on the first day of ICU admission, presence of shock upon presentation, source of infection, and number of preexisting risk factors for AKI (ie, creatinine level >177 μmol/L and history of diabetes, congestive heart failure, hypertension, or chronic nonsteroidal antiinflammatory drug use) [11] .
Vancomycin has known nephrotoxic properties and may thus contribute to the development of AKI. To assess the possibility of synergy between gentamicin and vancomycin toxicity, we also performed a sensitivity analysis in which an interaction term was included in the multivariable model.
All analyses were performed using SAS 9.2 (Cary, North Carolina) and R 2.15.1 software (R Foundation for Statistical Computing, Vienna, Austria). Data are presented as means with standard deviation (SD) or medians with interquartile range (IQR) as appropriate. We compared groups using nonparametric tests for continuous variables and χ 2 test for categorical variables. P values <.05 were considered to be statistically significant.
RESULTS
In total, 1457 patients were admitted with severe sepsis or septic shock during the study period, of whom 648 remained after application of exclusion criteria; 245 of these received gentamicin and 403 did not. The median duration of gentamicin exposure was 2 (IQR, 1-3) days and the median dose was 4.9 (IQR, 4.2 -5.0) mg/kg. Intraabdominal infections were most prevalent (n = 317; 49%) followed by urinary tract infections (n = 96; 15%), whereas the source of infection remained unknown in 183 patients (28%). Patients who received gentamicin were younger, had fewer comorbidities, and thus fewer risk factors for renal failure at baseline. However, the (acute) severity of disease upon presentation to the ICU was similar in both groups (Table 1) .
Differences in Management Between Patients Receiving and Not Receiving Gentamicin
Fluid management during the first 72 hours of ICU admission was comparable between both groups. Although the overall incidences of vasoactive drug use were similar, mean administered doses were higher in patients who received gentamicin (Table 1) . Nonetheless, mean arterial blood pressure during the first 3 days in the ICU did not differ (lowest observed hourly value per day was 57 (SD, 0.44) vs 57 (SD, 0.31) mm Hg; P = .78). In addition to the obvious difference in gentamicin use, vancomycin and metronidazole were more frequently administered during the first 3 days of ICU admission in patients who also received gentamicin, whereas carbapenems and quinolones were more frequently used in those who did not receive gentamicin (Table 2) .
Antimicrobial Resistance and Appropriateness of Antibiotic Therapy
Based on microbiological culture results of (surveillance) samples obtained in the period ranging from 2 days before until 2 days after ICU admission, 3 of 648 (0.5%) patients carried meropenem-resistant bacteria (ie, 2 cases of Pseudomonas aeruginosa and 1 case of Stenotrophomonas maltophilia), 65 (10%) carried third-generation cephalosporin-resistant bacteria, 49 (8%) carried ciprofloxacin-resistant bacteria, 16 (2%) carried piperacillin-tazobactam-resistant bacteria, and 38 (6%) carried gentamicin-resistant bacteria. Based on in vitro susceptibilities, 27 (4%) patients received inappropriate gram-negative antimicrobial coverage within the first 24 hours; 9 of 245 (4%) and 18 of 403 (4%) patients treated and not treated with gentamicin, respectively (P = .62). Stratified per ICU: 14 of 309 (5%) and 13 of 339 (4%) patients received inappropriate gram-negative antimicrobial coverage in ICU A and B, respectively (P = .66).
Of patients receiving combination therapy with gentamicin, 21 of 245 (9%) had gram-negative microorganisms that were only sensitive to gentamicin but resistant to the remaining given empirical antibiotics.
Association With Clinical Outcomes
The cumulative incidence of renal failure at day 14 was 113 (46%) in gentamicin-exposed and 156 (39%) in nonexposed patients (P = .06); the median number of renal failure-free days alive at day 14 was 12 (IQR, 0-14) and 14 (IQR, 0-14), respectively (P = .04; Table 3 ). Of note, the observed prevalence of (persisting) renal failure was 21 (12%) and 30 (10%) on day 14 (P = .39) in the subgroup of 484 patients who survived beyond this time point. In multivariable analysis with adjustment for imbalances in patient and disease characteristics at baseline, gentamicin exposure remained associated with more renal failure days (adjusted odds ratio [aOR], 1.39; 95% confidence interval [CI], 1.00-1.94; Table 4 ). Other independent risk factors for renal failure included advanced age, a greater number of preexisting risk factors for AKI, a medical (rather than a surgical) reason for ICU admission, and the presence of shock upon presentation to the ICU (Supplementary Table 1 ).
In crude analysis of the 381 patients who were admitted with septic shock at baseline, the median time to reversal of shock was 7 (IQR, 3-14) vs 4 (IQR, 2-14) days in patients who received or did not receive gentamicin, respectively (P < .01). In patients who were admitted without septic shock, vasopressor requirement eventually developed in 50 of 95 (53%) and in 86 of 127 (50%) patients, respectively (P = .68). In the multivariable model, gentamicin was no longer statistically significantly associated with duration of shock (aOR, 1.34; 95% CI, 0.96-1.86).
Crude mortality at day 14 was 72 (29%) in gentamicin-exposed and 92 (23%) in nonexposed patients (P = .06), yielding an aOR of 1.41 (95% CI, 0.94-2.12) in multivariable analysis. In part as a result of this, ICU length of stay was 4 days (IQR, 2-11) in exposed vs 7 days (IQR 3-15) in nonexposed patients (P < .01).
Sensitivity Analyses
In order to test the robustness of our findings, we performed a secondary intention-to-treat analysis and also assessed the The primary outcome represents a composite of death and renal failure occurrence (modeled as the number of days alive and free of renal failure on day 14). In the ordinal logistic regression model, odds ratios >1 correspond to a lower number of event-free days, implying a higher incidence of renal failure and/or a greater duration of renal failure and/ or higher death rates. Similarly, the secondary outcome of shock-free days represents a composite of death and shock occurrence (modeled as the number of days alive and free of cardiovascular shock on day 14). Death before day 14 was analyzed as a binary outcome in a logistic regression model. a Adjusted for age, ethnicity, medical reason for intensive care unit admission, number of risk factors for acute kidney injury, SOFA (sequential organ failure assessment ) score day 1, source of infection, and septic shock at baseline (latter for clinical outcome measures renal failure and 14-day mortality only).
effects of adding extra covariables to the multivariable models used in the primary analyses. The number of patients who received gentamicin was 222 of 309 (72%) in hospital A and 23 of 339 (7%) in hospital B. The cumulative incidence of renal failure was 46% in hospital A and 38% in hospital B (P = .04). After adjustment for potential confounders, the aORs associated with an empirical gentamicin strategy in the intention-to-treat analysis were 1.70 (1.22-2.36) for renal failure, 1.28 (0.93-1.77) for duration of shock, and 1.76 (1.17 -2.64) for day-14 mortality (Table 4) . Adding vancomycin use to the primary multivariable model did not change the association between gentamicin use and renal failure (aOR, 1.41; 95% CI, 1.00-1.99). Furthermore, interaction of gentamicin and vancomycin toxicity was not observed (P value for the interaction term = .16).
In the subgroup of day-14 survivors (n = 484), the effect estimate for the association between gentamicin exposure and renal failure-free days was similar to the effect size quantified by our primary analysis (aOR, 1.33; 95% CI, 0.86-2.07 vs 1.39). Similarly, the effect estimate for the association with shock duration was comparable to that observed in the total study cohort (aOR, 1.25; 95% CI, 0.78-1.99 vs 1.34). Second, in patients with abdominal sepsis (n = 317), the effect estimate for the association with renal failure was comparable to that observed in the primary analysis (aOR, 1.47; 95% CI, 0.91-2.38 vs 1.39).
DISCUSSION
We found that addition of gentamicin to empirical treatment with third-generation cephalosporins in patients admitted to the ICU with severe sepsis or septic shock was not associated with better patient outcomes. In fact, our findings suggest that exposure to gentamicin of 2 days median duration is associated with the development of AKI.
To the best of our knowledge, only 2 retrospective studies have assessed the effects of short-course gentamicin as part of an empirical antibiotic regimen in patients with sepsis [17, 18] . In the first study no differences in the occurrence of AKI or mortality were observed in 150 patients who received gentamicin or amikacin compared to 64 patients who did not receive aminoglycosides. Yet, patients with renal failure documented before day 3 in the ICU were excluded from the study, which reduced the overall incidence of renal failure by more than half and may thus have obscured any early nephrotoxicity [17] . In the second study, which was among patients who visited an emergency department with possible sepsis, 179 patients who received only a single dose of gentamicin were compared to 123 patients who did not receive gentamicin [18] . AKI occurred in 6.7% vs 3.3% of patients, but this difference did not reach statistical significance (P = .30). Both studies thus suffered from limited sample size, which hampered the power to demonstrate clinically relevant differences.
In contrast, our study included a larger sample size, and clinical data were prospectively collected using validated protocols [14] , which minimized the risk of information bias. Furthermore, the unequivocal difference in antibiotic policies between the 2 participating ICUs created a natural experiment for evaluating the effects of gentamicin. Yet, as adherence to local antibiotic policies was not perfect, there remained a risk of confounding by indication. Of note, our study patients with preexisting risk factors for AKI, such as elevated baseline creatinine levels, diabetes mellitus, congestive heart failure, or hypertension, were less likely to receive gentamicin, which probably reflects selection by caregivers. This implies that the true incidence of nephrotoxicity caused by gentamicin may be underestimated in unadjusted analyses. Therefore, we also compared both ICUs in a secondary "intention-to-treat according to local protocol" analysis, while adjusting for differences in case mix, yet obtained comparable results, as was the case in subgroups of day-14 survivors and patients with abdominal sepsis. Nonetheless, the presence of some residual confounding in an observational study cannot be excluded, and limitations with regard to the interpretation of our results must thus be considered. First, our study was performed in 2 tertiary care centers in the Netherlands and thus may not reflect ICU practice in all settings, especially in those with higher prevalences of multidrug-resistant microorganisms. Second, there were subtle differences in various aspects of clinical management between the 2 participating ICUs, which may have contributed to the observed outcome differences. One difference concerned the more frequent use of carbapenems and quinolones in hospital A. The lower incidence of renal failure and a trend toward better patient outcome associated with avoiding gentamicin exposure in our study must be balanced against the observed 11% more frequent usage of carbapenems and 7% more frequent usage of quinolones. Third, we did not evaluate the occurrence of AKI beyond day 14, and thus it could be that the consequences of gentamicin use on long-term renal function are less apparent. Fourth, dosing of gentamicin in our study was based on 5-mg/kg bodyweight, whereas some centers advocate the use of higher doses [19] [20] [21] . Of note, in the hospital that administered gentamicin as part of the empirical treatment protocol, therapeutic drug monitoring was used in virtually all patients, with both peak and trough levels being obtained after the first dose to guide further dosing. Therapeutic drug monitoring presumably lowers the risk of both under-and overdosing, yet the association between gentamicin use and kidney injury was still observed in this setting.
In conclusion, an empirical antibiotic approach that includes gentamicin therapy as an initial adjunct in critically ill patients admitted to the ICU with severe sepsis or septic shock was not associated with faster reversal of shock or improved survival but was associated with a higher incidence of renal failure. These findings do not support the practice of adding short courses of gentamicin to empirical antibiotic treatment in ICU settings with a low prevalence of antibiotic resistance.
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